![[Search]](/static/images/search.gif){kind=small}
![[A-Z Index]](/static/images/az.gif){kind=small}
![[Contact]](/static/images/contact.gif){kind=small}
![[University of Cambridge]](/static/images/identifier2.gif){kind=small}
![[Talks.cam]](/static/images/talkslogosmall.gif)
Thursday 28 March 2024, 10:00-11:00
Genetics for drug discovery, going beyond target ID
â ī¸ Important: Please sign up at: https://www.ticketsource.co.uk/university-of-cambridge/genetics-for-drug-discovery-going-beyond-target-id-joanna-mccammond-mcgill-howson/e-raprpr
- đ¤ Speaker: Joanna McCammond McGill Howson (Vice President at Novo Nordisk Research Centre Oxford)
- đ Date & Time: Thursday 28 March 2024, 10:00 - 11:00
- đ Venue: Zoom: https://sanger.zoom.us/j/99447320668?pwd=NmdRbEJ0WDVRODZjemprZ2ZyWXBkQT09 OR In-person at HLRI (bottom floor seminar rooms, Addenbrookes campus)
Questions? Contact
Spencer Keene
Abstract
At Novo Nordisk, we have a human centric approach to drug discovery, for example by harnessing human genetics and integrating other omics and data types to identify potential targets in cardiometabolic diseases. That targets with human genetics support are more likely to be successful in clinical development, is well established. What is less often discussed is, can we further leverage human data to help develop therapies for patients? I will highlight a few examples of what we are thinking about in relation to using human genetics at Novo Nordisk, beyond target identification.
Series This talk is part of the HDR UK Cambridge Seminar Series series.
Included in Lists
- HDR UK Cambridge Seminar Series
- ndk22's list
- Zoom: https://sanger.zoom.us/j/99447320668?pwd=NmdRbEJ0WDVRODZjemprZ2ZyWXBkQT09 OR In-person at HLRI (bottom floor seminar rooms, Addenbrookes campus)
Note: Ex-directory lists are not shown.